Uses
Rasagiline tablets are indicated for the treatment of Parkinson’s disease (PD). Rasagiline, a monoamine oxidase (MAO)-B inhibitor (MAOI), is indicated for the treatment of Parkinson’s disease
Source: US FDA prescribing information
- Presentations
- 4
- Brands
- 1
- Manufacturers
- 1
- Available from stock
- 0
Rasagiline is a monoamine oxidase inhibitor indicated for the treatment of Parkinson’s disease (PD). It is available as tablets for oral use. MedsAcross supplies Rasagiline for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Key facts
- Pharmacological class
- Monoamine Oxidase Inhibitor, Monoamine Oxidase Inhibitors
- ATC classification
- N04BD02 Rasagiline · Dopaminergic, subgroup N04BD
- US FDA first approval
- 16 May 2006
- EU status
- Authorised
- Orphan designation
- No
- WHO essential medicine
- Not recorded
- India (CDSCO)
- Not yet confirmed against CDSCO approval lists
- Routes
- Oral
- Dosage forms
- Tablet
- Identifiers
- UNII 003N66TS6TRxCUI 134748CAS 136236-51-6DrugBank DB01367Q420685
Clinical information
From the regulator-approved product information. Each section names its source.
How it works
Rasagiline is a selective, irreversible MAO-B inhibitor indicated for the treatment of idiopathic Parkinson’s disease. The results of a clinical trial designed to examine the effects of rasagiline on blood pressure when it is administered with increasing doses of tyramine indicates the functional selectivity can be incomplete when healthy subjects ingest large amounts of tyramine while receiving recommended doses of rasagiline. The selectivity for inhibiting MAO-B diminishes in a dose-related manner. MAO, a flavin-containing enzyme, is classified into two major molecular species, A and B, and is localized in mitochondrial membranes throughout the body in nerve terminals, brain, liver and intestinal mucosa. MAO regulates the metabolic degradation of catecholamines and serotonin in the CNS and peripheral tissues. MAO-B is the major form in the human brain.
Source: US FDA prescribing information
Dosing overview
Monotherapy: rasagiline 1 mg once daily. As adjunct without levodopa: rasagiline 1 mg once daily. As adjunct to levodopa: rasagiline 0.5 mg once daily. Increase dose to 1 mg daily as needed for sufficient clinical response. Patients taking ciprofloxacin or other CYP1A2 inhibitors: rasagiline 0.5 mg once daily. Patients with mild hepatic impairment: rasagiline 0.5 mg once daily. Rasagiline should not be used in patients with moderate or severe hepatic impairment
Source: US FDA prescribing information
Contraindications
Rasagiline is contraindicated for use with meperidine, tramadol, methadone, propoxyphene, and MAO inhibitors (MAOIs), including other selective MAO-B inhibitors, because of risk of serotonin syndrome. At least 14 days should elapse between discontinuation of rasagiline and initiation of treatment with these medications. Rasagiline is contraindicated for use with St. John’s wort and with cyclobenzaprine. Rasagiline is contraindicated for use with dextromethorphan because of risk of episode of psychosis or bizarre behavior. Concomitant use of meperidine, tramadol, methadone, propoxyphene dextromethorphan, St. John’s wort, cyclobenzaprine, or another (selective or non-selective) MAO inhibitor
Source: US FDA prescribing information
Warnings and precautions
May cause hypertension (including severe hypertensive syndromes) at recommended doses. May cause serotonin syndrome when used with antidepressants. May cause falling asleep during activities of daily living, daytime drowsiness, and somnolence. May cause hypotension, especially orthostatic. May cause or exacerbate dyskinesia. Decreasing the levodopa dose may lessen or eliminate this side effect. May cause hallucinations and psychotic-like behavior. May cause impulse control/compulsive behaviors. May cause withdrawal-emergent hyperpyrexia and confusion
Source: US FDA prescribing information
Side effects
The following adverse reactions are described in more detail in the Warnings and Precautions section of the label: Hypertension Serotonin Syndrome Falling Asleep During Activities of Daily Living and Somnolence Hypotension / Orthostatic Hypotension Dyskinesia Hallucinations / Psychotic-Like Behavior Impulse Control /Compulsive Behaviors Withdrawal-Emergent Hyperpyrexia and Confusion Most common adverse reactions (incidence 3% or greater than placebo): Rasagiline monotherapy: flu syndrome, arthralgia, depression, dyspepsia. Rasagiline used as adjunct without levodopa: peripheral edema, fall, arthralgia, cough, and insomnia. Rasagiline used as adjunct to levodopa: dyskinesia, accidental injury, weight loss, postural hypotension, vomiting, anorexia, arthralgia, abdominal pain, nausea, constipation, dry mouth, rash, abnormal dreams, fall, and tenosynovitis
Source: US FDA prescribing information
Interactions
Meperidine: Risk of serotonin syndrome. Dextromethorphan: Risk of psychosis or bizarre behavior. MAO inhibitors: Risk of non-selective MAO inhibition and hypertensive crisis
Source: US FDA prescribing information
Storage
Store at 25°C (77°F) with excursions permitted to 15°-30°C (59°-86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
All presentations
4 presentations of Rasagiline, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Rasagiline 1 mg tabletOralGeneric name | — | US FDA | Available on request |
| Rasagiline 0.5 mg tabletOralGeneric name | — | US FDA | Available on request |
| Azilect 0.5 mg tabletOral | Teva Neuroscience | US FDA | Available on request |
| Azilect 1 mg tabletOral | Teva Neuroscience | US FDA | Available on request |
Brands by market
1 brand names across 1 markets.
United States
Manufacturers
Regulatory status
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions
Conditions linked to Rasagiline in public data. This is not a list of approved uses, see the clinical information.
Questions and answers
Is Rasagiline available for export from India?
Yes, on request. MedsAcross lists 4 presentations of Rasagiline and sources them for licensed hospitals, importers and physicians against valid import documents.
What brand names does Rasagiline have?
The catalogue lists 1 brand names for Rasagiline, including Azilect.
Is Rasagiline approved by the US FDA?
Yes. The US FDA first approved Rasagiline on 16 May 2006, according to Drugs@FDA.
Is Rasagiline authorised in the European Union?
Yes. Rasagiline has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
Does Rasagiline need cold chain shipping?
No listed presentation of Rasagiline is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Which ATC class is Rasagiline in?
Rasagiline is classified under ATC code N04BD02 (Rasagiline).
References
- Rasagiline prescribing information (Teva Pharmaceuticals). U.S. National Library of Medicine, DailyMed. Retrieved 30 June 2020
- Azilect: European public assessment report (EPAR). European Medicines Agency. Retrieved 8 April 2025
- Rasagiline ratiopharm: European public assessment report (EPAR). European Medicines Agency. Retrieved 9 April 2025
Request Rasagiline for export supply
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.